Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5‑fluorouracil by regulating β‑catenin and cyclin D1 expression

Wang,Chong; Guo,Yu; Wang,Jing; Min,Zhiqun

doi:10.3892/mmr.2014.2906

Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5‑fluorouracil by regulating β‑catenin and cyclin D1 expression

Authors:
- Chong Wang
- Yu Guo
- Jing Wang
- Zhiqun Min
View Affiliations

Affiliations: Department of Basic Medical Sciences of Medical College, Xiamen University, Xiamen, Fujian 361102, P.R. China, Department of Hepatic Surgery, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Clinical Laboratory Center of Molecular Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China
Published online on: November 10, 2014 https://doi.org/10.3892/mmr.2014.2906
Pages: 2147-2152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancer types, and chemotherapy plays an important role in treatment of HCC. However, long‑term treatment with chemotherapeutic drugs such as 5‑fluorouracil (5‑FU) often results in chemoresistance, and the underlying mechanisms remain unclear. In this study, we showed that the annexin A2 (ANXA2) protein is highly expressed in hepatoma cells compared to healthy cells. Knockdown of the ANXA2 gene inhibited hepatoma cell growth, and the underlying mechanism may involve cell cycle inhibition through downregulation of β‑catenin and cyclin D1. We also investigated the role of ANXA2 in chemotherapeutic treatment with 5‑FU. 5‑FU inhibited hepatoma cell growth, while ANXA2 overexpression reduced, and knockdown enhanced, the effects of 5‑FU on hepatoma cell growth. Furthermore, β‑catenin and cyclin D1 were asscociated with the ANXA2‑induced resistance. Taken together, our data suggest that the ANXA2 protein is a critical factor in HCC and that its downregulation can enhance chemotherapeutic treatment with 5‑FU. ANXA2 may thus constitute a new therapeutic target for HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
3	Pérez-Tomás R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
4	O’Connor R: A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets. 9:273–280. 2009. View Article : Google Scholar
5	Gerke V, Creutz CE and Moss SE: Annexins: linking Ca²⁺ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 6:449–461. 2005. View Article : Google Scholar : PubMed/NCBI
6	Zhang X, Liu S, Guo C, Zong J and Sun MZ: The association of Annexin A2 and cancers. Clin Transl Oncol. 14:634–640. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bharadwaj A, Bydoun M, Holloway R and Waisman D: Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 14:6259–6305. 2013. View Article : Google Scholar : PubMed/NCBI
8	Wu B, Zhang F, Yu M, et al: Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell Prolif. 45:189–198. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K and Tachibana M: Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 101:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
10	Emoto K, Sawada H, Yamada Y, et al: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 21:1339–1345. 2001.PubMed/NCBI
11	Gao H, Yu B, Yan Y, et al: Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg. 118:846–853. 2013. View Article : Google Scholar
12	Bao H, Jiang M, Zhu M, Sheng F, Ruan J and Ruan C: Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gillette JM, Chan DC and Nielsen-Preiss SM: Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem. 92:820–832. 2004. View Article : Google Scholar : PubMed/NCBI
14	Pena-Alonso E, Rodrigo JP, Parra IC, et al: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett. 263:89–98. 2008. View Article : Google Scholar : PubMed/NCBI
15	Longerich T, Haller MT, Mogler C, et al: Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract. 207:8–14. 2011. View Article : Google Scholar
16	Mohammad HS, Kurokohchi K, Yoneyama H, et al: Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol. 33:1157–1163. 2008.PubMed/NCBI
17	Zhang HJ, Yao DF, Yao M, et al: Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol. 18:5897–5904. 2012. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Zhao P, Xu XL, et al: Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One. 8:e672682013. View Article : Google Scholar : PubMed/NCBI
19	Ye X, Guo Y, Zhang Q, et al: βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar
20	Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 103:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kanda T, Yokosuka O, Imazeki F, Arai M and Saisho H: Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol. 24:805–809. 2005. View Article : Google Scholar : PubMed/NCBI
22	Wong CM, Fan ST and Ng IO: beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 92:136–145. 2001. View Article : Google Scholar : PubMed/NCBI
23	Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES and Buendia MA: Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 155:703–710. 1999. View Article : Google Scholar : PubMed/NCBI
24	Herencia C, Martinez-Moreno JM, Herrera C, et al: Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One. 7:e346562012. View Article : Google Scholar
25	Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI
26	Zhang YJ, Jiang W, Chen CJ, et al: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 196:1010–1016. 1993. View Article : Google Scholar : PubMed/NCBI
27	Zeng G, Apte U, Cieply B, Singh S and Monga SP: siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 9:951–959. 2007. View Article : Google Scholar : PubMed/NCBI
28	Waly Raphael S, Yangde Z and Yuxiang C: Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol. 2012:4216732012.PubMed/NCBI
29	Tong SW, Yang YX, Hu HD, et al: Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem. 113:1671–1680. 2012.
30	Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658. 2009. View Article : Google Scholar : PubMed/NCBI